Rituximab
- PDF / 168,791 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 2 Downloads / 157 Views
1 S
Infusion-related anaphylaxis: case report In a study involving 10 patients (received obinutuzumab between January 2015 and December 2019), a patient [age and sex not stated] was described, who developed infusion-related anaphylaxis while receiving rituximab [dosage and duration of treatment to reaction onset not stated] for membranous nephropathy. Therefore, rituximab was switched to obinutuzumab [outcome not stated]. Sethi S, et al. Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney International Reports 5: 1515-1518, No. 9, Sep 2020. Available 803505350 from: URL: http://doi.org/10.1016/j.ekir.2020.06.030
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
